Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group

Maria Gabriella Ferrandina, Giovanni Scambia, Manuela Ludovisi, D Lorusso, S Pignata, R Viganò, S Scalone, P Scollo, E Breda, A Pietragalla

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The objective of the study was to estimate the antitumor activity of pemetrexed in patients with advanced/recurrent carcinoma of the cervix and to determine the nature and degree of toxicity.
Original languageEnglish
Pages (from-to)61-66
Number of pages6
JournalAnnals of oncology : official journal of the European Society for Medical Oncology / ESMO
Volume21
DOIs
Publication statusPublished - 2010

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents
  • Carcinoma
  • Disease-Free Survival
  • Female
  • Glutamates
  • Guanine
  • Humans
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Uterine Cervical Neoplasms

Fingerprint

Dive into the research topics of 'Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group'. Together they form a unique fingerprint.

Cite this